Supernus Pharmaceuticals Analyst Ratings
Supernus Pharmaceuticals Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 01/23/2023 | 16.6% | Piper Sandler | $40 → $47 | Maintains | Overweight |
| 08/31/2022 | -5.73% | Piper Sandler | $33 → $38 | Maintains | Overweight |
| 04/13/2021 | -0.77% | Jefferies | $25 → $40 | Upgrades | Hold → Buy |
| 06/16/2020 | -23.1% | Piper Sandler | $25 → $31 | Upgrades | Neutral → Overweight |
| 06/15/2020 | -40.46% | Jefferies | → $24 | Reinstates | → Hold |
| 04/16/2020 | -40.46% | Stifel | $25 → $24 | Maintains | Hold |
| 11/07/2019 | -42.94% | Stifel | $55 → $23 | Downgrades | Buy → Hold |
| 11/06/2019 | — | Jefferies | Downgrades | Buy → Hold | |
| 12/17/2018 | 56.29% | Mizuho | $61 → $63 | Maintains | Buy |
| 11/12/2018 | 61.25% | B. Riley Securities | $68 → $65 | Maintains | Buy |
| 09/18/2018 | 51.33% | Mizuho | → $61 | Initiates Coverage On | → Buy |
| 08/09/2018 | 43.88% | Jefferies | $55 → $58 | Maintains | Buy |
| 05/25/2018 | 48.85% | Stifel | $50 → $60 | Maintains | Buy |
| 02/01/2018 | 63.73% | Berenberg | → $66 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目标价格变化 | 评级变化 | 上一次/当前评级 |
|---|---|---|---|---|---|
| 2023年1月23日 | 16.6% | 派珀·桑德勒 | $40→$47 | 维护 | 超重 |
| 2022年08月31日 | -5.73% | 派珀·桑德勒 | $33→$38 | 维护 | 超重 |
| 04/13/2021 | -0.77% | 杰富瑞 | $25→$40 | 升级 | 持有→购买 |
| 06/16/2020 | -23.1% | 派珀·桑德勒 | $25→$31 | 升级 | 中性→超重 |
| 2020/06/15 | -40.46% | 杰富瑞 | →$24 | 恢复 | →保留 |
| 04/16/2020 | -40.46% | Stifel | $25→$24 | 维护 | 保持 |
| 2019/07/11 | -42.94% | Stifel | $55→$23 | 评级下调 | 购买→Hold |
| 2019/06/11 | - | 杰富瑞 | 评级下调 | 购买→Hold | |
| 2018年12月17日 | 56.29% | 瑞穗 | $61→$63 | 维护 | 买 |
| 2018年11月12日 | 61.25% | B.莱利证券 | $68→$65 | 维护 | 买 |
| 2018年09月18日 | 51.33% | 瑞穗 | →$61 | 开始承保 | →购买 |
| 2018年08月09日 | 43.88% | 杰富瑞 | $55→$58 | 维护 | 买 |
| 2018年05月25日 | 48.85% | Stifel | $50→$60 | 维护 | 买 |
| 2018年02月01日 | 63.73% | 贝伦伯格 | →$66 | 开始承保 | →购买 |
What is the target price for Supernus Pharmaceuticals (SUPN)?
Supernus PharmPharmticals(SUPN)的目标价是多少？
The latest price target for Supernus Pharmaceuticals (NASDAQ: SUPN) was reported by Piper Sandler on January 23, 2023. The analyst firm set a price target for $47.00 expecting SUPN to rise to within 12 months (a possible 16.60% upside). 2 analyst firms have reported ratings in the last year.
派珀·桑德勒于2023年1月23日报道了Supernus制药公司(纳斯达克代码：SUPN)的最新目标价。这家分析公司将目标价定为47.00美元，预计SUPN将在12个月内上涨至16.60%(可能上涨16.60%)。去年有两家分析公司公布了评级。
What is the most recent analyst rating for Supernus Pharmaceuticals (SUPN)?
Supernus PharmPharmticals(SUPN)的最新分析师评级是多少？
The latest analyst rating for Supernus Pharmaceuticals (NASDAQ: SUPN) was provided by Piper Sandler, and Supernus Pharmaceuticals maintained their overweight rating.
分析师对Supernus PharmPharmticals(纳斯达克代码：SUPN)的最新评级由Piper Sandler提供，Supernus PharmPharmticals维持其增持评级。
When is the next analyst rating going to be posted or updated for Supernus Pharmaceuticals (SUPN)?
Supernus PharmPharmticals(SUPN)的下一次分析师评级将于何时发布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Supernus Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Supernus Pharmaceuticals was filed on January 23, 2023 so you should expect the next rating to be made available sometime around January 23, 2024.
分析师在进行了广泛的研究后得出了股票评级，其中包括查阅公共财务报表，与Supernus制药公司的高管和客户交谈，以及听取收益电话会议。大多数分析师每三个月就会这样做一次，所以你每年应该会得到每家公司每家公司的4个评级。Supernus制药的上一次评级是在2023年1月23日提交的，所以你应该预计下一次评级将在2024年1月23日左右的某个时候公布。
Is the Analyst Rating Supernus Pharmaceuticals (SUPN) correct?
分析师对Supernus PharmPharmticals(SUPN)的评级正确吗？
While ratings are subjective and will change, the latest Supernus Pharmaceuticals (SUPN) rating was a maintained with a price target of $40.00 to $47.00. The current price Supernus Pharmaceuticals (SUPN) is trading at is $40.31, which is within the analyst's predicted range.
虽然评级是主观的，并将发生变化，但最新的Supernus PharmPharmticals(SUPN)评级维持不变，目标价在40.00美元至47.00美元之间。Supernus PharmPharmticals(SUPN)目前的交易价格为40.31美元，在分析师的预测区间内。